Busy AF - unless I'm not.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've said it before - as recently as October of 2023, the Bluebird website had "multiple undisclosed" featured on their pipeline page.
October 1 2023, 11:56:07
https://web.archive.org/web/20231001115607/https://www.bluebirdbio.com/our-science/pipeline
why?
If the concept of DEIB is not in accordance with business objectives of BLUE, then the entirety of the companies goals are irrelevant and meaningless.
I was starting to believe the 10Q and 10K weren't going to happen. But they did. Patiently waiting on the 10Q for 2024 Q2.
https://investor.bluebirdbio.com/sec-filings/sec-filing/10-k/0001293971-24-000037
https://investor.bluebirdbio.com/sec-filings/sec-filing/10-q/0001293971-24-000040
I still say BLUE was shot in the face by the FDA w the BB warning, AND that the SEC should investigate. Based on the trades over the last few weeks, I'm still bullish - but defeated enough that I cannot in good faith post that green bull.
Be easy, Bluebirds.
I figure FMV as of Sept 1st, just with cash on hand, is ~$0.75. This does not account for cash flows from Qtr 2 '24 Lyfgenia, nor from Q 3 and 4 sales of all three. Skysona, for CALD, is the biggest of the three approved therapies, IMO. Lyfgenia (Sickle Cell) is great, but when you get to stopping and/or repairing mitochondria damage, that's just amazing. The therapy market for Skysona may only be in the tens, but the future markets are much, much larger.
Huge sell-off today - 3.6m buys vs 7.1 m sells - and it closes down less than 2%.
Finally, we have Hercules backing BLUE. That's pretty huge.
Ain't no stopping this train.
Buys clearing sales at 2:1 on close today. Have a relaxing weekend!
I have arguments.
Seemed like a good day to buy the dip.
That's a nice average - beats mine by a lot!! I hope you're into the long-term.
Seriously? What does this have to do with the actual company?
We've already covered my query of your bearish to bullish flip a few months back; given the content of these posts and the time frame ($20, $18, $10, $100!), you are stead-fast super-bullish, contrary to your post and response from....February?, questioning experience and why bullish. Not to be rude, just wondering where your aces are. All I've got is 4 chips, a chair, and a belief in two things: Coincidence and Einmal ist Keinmal (Once is insignificant). I have other things, too - like substantial recognized losses, as well as substantial unrealized losses here and elsewhere. I have a bit more in our pocket that may be worth all the rest - I have a feeling that Skysona and the associated data set may hold incredible value for addressing both Alzheimers and Substance Abuse/Addiction.
I'm looking for more content like a blind man who can feel the sun. You're the only moderator. Posts should be relevant to the substance of the company - not potshots.
I'm sorry you're frustrated, it is understandable. What is NOT understandable is why the FDA would approve lovo-cel/Lyfgenia with a Black Box warning. As I have already said, if the BB warning holds merit, the hold should never have been lifted in the first place. To be clear, THAT is where I think you should focus your frustrations - the hit job by the FDA. Any lawyers worth their salt aren't involved in this class action. IMHO.
The SEC should absolutely be investigating Dec 8 2023 stock action on CRSP and BLUE with special deference to the FDA.
"bluebird has the largest and deepest ex-vivo gene therapy data set in the field".
This class action is dark times - but it's misplaced, and it will fail, with one of the defensible factors being the removal of "multiple undisclosed" from the pipeline page. That's not a pocket-ace for the sharks, if ya follow. I feel for those that lost, and I am down also - but this is solely on the FDA, and nobody's gonna sue them, sadly. All these sharks...trying to hold Bluebird accountable for ...forward-planning and a lack of caution by analysts?? Geez...the type-set was clear.
Pretty good buy action today, IMO. I've got a little left in the tank, and I see no reason to assume 30%+ share equity increase, but baking-in the value of 2500 therapy instances on 200m is a lot to wrap. Back to top, future...................unknown.
Irrefutable...changed my mind, had to increase the position.
You should post more. I have faith in Gina Wang's rating, and I also believe whether or not the first patient receiving Lyfgenia needs to have a second cell collection is going to be influential in significant ways.
Hmm. Coulda sworn I heard the bell. 17:34, 05.07.2024.
There are *THREE* approved curative therapies. Adrenoleukodystrophy, Beta Thalassemia, and Sickle Cell.
IMO, this should be at least $5. But there's that word: Future. Unknown.
Money is nice. Being able to live, and live pain free - that's much nicer.
bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
Published: May 06, 2024
https://www.biospace.com/article/releases/bluebird-bio-announces-completion-of-first-cell-collection-for-lyfgenia-gene-therapy/
I can only answer by pointing to one operative word in my post, and that is undefined, for no one knows what it will bring. That word is "future".
As an early childhood survivor of an Astrocytoma and a recipient of blood transfusions prior to 1983, I have significant interest in all three of their drugs - from neurological issues to blood issues. Clearly, I have no shame and am not afraid.
Some call it investing, others call it gambling. I may sell, but I am inclined it "let it ride". If I sell, it is only bc I need liquidity. As with all ventures, one should not engage unless they are willing to lose it all. I can't afford to lose it all, but I'm still here. And I am grateful for that.
Finally, the major issue to contend with is bad actors. I assure you I am not - but I can only ask that people have faith that my actions and intentions are pure of heart.
I'll tell you what I think, friend - I'm eager for earnings on the 7th, although I'm fairly positive we will not see them for another few weeks after that date. I think that the class action is going to fail, that patient starts across all three drugs is going to exceed the minimum forecast of...what was it, 80 patient starts?, and that BLUE is going to skyrocket in the future, becoming the talk of wall street.
At any rate, I'm not buying anymore, even though today is/was my calendar day to avoid making wash sales. I will say that I may sell at any given point in time - the volatility is nerve racking and times are getting tight, as it were.... But much like a certain other person, I like the stock. I like the stock a LOT.
The Gross law firm has filed a class action lawsuit against Bluebird on behalf of shareholders who purchased between April 24 2023 and December 8 2023.
IMO, Blue has not committed the securities law violations alleged (which have not been named or enumerated, btw), and any lawsuit going forward should be filed against the FDA for their issuance of the "Blackbox" warning. Blue stated previously they intend to address the non-award of the PRV with the FDA. They should also be pursuing removal of the "Blackbox" warning; if the Blackbox warning had teeth, the clinical trial hold should never have been lifted in the first place - but the FDA vindicated BLUE from this previously. Furthermore, if BLUE did commit securities fraud (again, unspecified how), then that falls onto the regulatory agency moreso than BLUE, IMO.
Honestly - if not a single analyst anticipated the Blackbox warning, this is all a malignant waste of time by the FDA.
[ALLEGATIONS: According to the complaint, on December 8, 2023, Blue announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs). However, the Lyfgenia approval came with a black box warning for haematological malignancies after two patients developed AML during the clinical trials. Analysts noted that they did not expect the black box warning or the absence of a priority review voucher. Following this news, Blue's stock price fell by $1.95 per share, or approximately 40% to close at $2.86 per share.]
That seeking alpha article is behind a paywall, unfortunately. I'm sure I wouldn't be the only happy person if you posted the sentences that you find informative.
I believe in the power of BlueBird's medicines, but I am concerned about the shorts, as I've had a ridiculous amount of calls get just completely disintegrated by the pressure on this stock in the last 2.5 years. Hopefully, we find that Blue management is honest and also correct about their projections going forward. In addition to that, I'm keeping my fingers crossed that it is Hercules's goal to help facilitate the healthcare options that BLUE has created, and not to steal the entirety of the companies I.P. The agreement does hinge somewhat on the company trading, if I am correct in my calculations, above $2.63 USD for the preceding 30 days of the first day of any financial quarter.
I've lost out significantly to other companies' management teams over the years that were malignant, and I am deeply disturbed that BLUE eliminated the graphic of "Misc Undisclosed" from their pipeline page in the summer of '23. I'm disappointed they haven't addressed that, and have significant thoughts about addressing management over the issue myself. If any of these class action examinations have solid footing, that is one aspect that will be exposed.
I will be reducing my holdings, starting next week, by ~11% for tax harvesting purposes, but I am not going anywhere. I am hoping it tanks a bit more so I can keep more than 89% of my current holdings.
I have a hard time cheering someone who posts 4 month old info without a qualifier that it is 4 month old information. Couple that with your sudden appearance and flip from bearish to bullish within 3 weeks of each other....
Nov 7, 2023 at 8:00 AM EST has long since passed.
Why did you post this?
FDA Ramrod x2, + shorts.
Been with KOAN for years. This is an understatement:
[illiquid stinky pink company]
[On February 20, 2024, Resonate Blends, Inc. (the “Company”) entered into a Share Exchange Agreement (the “Exchange Agreement”) with Emergent Health Corp., a Wyoming corporation (hereinafter referred to as “EMGE”), and the holders (the “EMGE Preferred Shareholders) of Series Class A Preferred Stock, the Series C Convertible Non-Voting Preferred Stock and the Class F Preferred Stock of EMGE (the “EMGE Equity Interests”).]
https://www.otcmarkets.com/filing/html?id=17305421&guid=Hcd-k6NQcN5eJth
That would be lovely, but what's your info?
At 190.4mm shares to 20 per, that's 3.8 Billion - or over 1000 drug sales at 2.75m avg. BLUE forecasted 80-100 sales this year.
I believe the bottom has come and gone. I wouldn't expect to see anything below $0.95 again.
This guy wants your shares of BLUE ruhl bad, me thinks.
No, but they said it was still desired. From early/mid December: https://www.otcmarkets.com/filing/html?id=17119345&guid=2QJ-kn8STt5PB3h
I think it's pretty obvious that KOAN management is only concerned with enriching themselves.
What's that about BLUE?
"In connection with the approval of LYFGENIA, we did not receive a Rare Pediatric Disease Priority Review Voucher that we requested as part of the FDA’s review. We are evaluating the FDA’s denial and plan to dispute this decision with the FDA."
https://ih.advfn.com/stock-market/NASDAQ/bluebird-bio-BLUE/stock-news/92864211/form-424b5-prospectus-rule-424b5
That's one interpretation, for sure.
There should have been an adcom meeting. This has been one hell of a hit job by the FDA, from the scheduling and early announcement for Lyfgenia, all the way back to the fall of '21.
IMO, the FTC should be examining anti-trust action against the FDA.
515,583 for an avg of 0.16227, currently down some 76k+...just lovely. The collapse of this deal w Pegasus is my final straw...lol, really. Holding until I have LT gains to offset the dump.
I've never sold any KOAN, but did sell and rebought some TXHD [?] (Can't recall the exact..) back "in the day" back to back. So I might come back to clear that....but I ain't leavin yet either.
Oh, of course.
It'll moon out someday, I'm not worried about any of that.
80% is ...wow.
"several more to go"
Say what?
12.13.2023 - 12.08.2023
782,500 new shares, restricted.
Outstanding Shares
86,623,596
12/08/2023
Restricted
54,560,665
12/08/2023
Unrestricted
32,062,931
12/08/2023
Held at DTC
31,265,725
12/08/2023